Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Cash & Equivalents (2021 - 2025)

Roivant Sciences' Cash & Equivalents history spans 5 years, with the latest figure at $1.5 billion for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 1391.95% year-over-year to $1.5 billion; the TTM value through Dec 2025 reached $1.5 billion, up 1391.95%, while the annual FY2025 figure was $2.7 billion, 58.19% down from the prior year.
  • Cash & Equivalents reached $1.5 billion in Q4 2025 per ROIV's latest filing, up from $1.2 billion in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $6.7 billion in Q4 2023 to a low of $94.8 million in Q2 2025.
  • Average Cash & Equivalents over 5 years is $2.3 billion, with a median of $2.0 billion recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: crashed 98.52% in 2024, then surged 1391.95% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $2.2 billion in 2021, then crashed by 31.02% to $1.5 billion in 2022, then surged by 338.64% to $6.7 billion in 2023, then plummeted by 98.52% to $99.1 million in 2024, then soared by 1391.95% to $1.5 billion in 2025.
  • Per Business Quant, the three most recent readings for ROIV's Cash & Equivalents are $1.5 billion (Q4 2025), $1.2 billion (Q3 2025), and $94.8 million (Q2 2025).